Experimental virus therapy targets Hard-to-Treat cancers in first human trial
Disease control
Recruiting now
This early-phase study tests a new treatment called VET3-TGI, a virus designed to attack cancer cells and boost the immune system. It is for adults with advanced solid tumors that have not responded to standard therapies. The study aims to find a safe dose when given alone or com…
Phase: PHASE1 • Sponsor: KaliVir Immunotherapeutics • Aim: Disease control
Last updated May 01, 2026 15:58 UTC